Context
In 2005, HEDIS introduced a quality measure to assess the receipt of disease modifying anti-rheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA).
Objective
To identify sociodemographic, community, and health-plan factors associated with DMARD receipt among Medicare managed care enrollees.
Design, Setting, and Patients
We analyzed individual-level HEDIS data for 93,143 patients ≥ 65 years old with at least 2 diagnoses of RA within a measurement year (during 2005–2008). Logistic regression models with generalized estimating equations were used to determine factors associated with DMARD receipt. We used logistic regression to adjust health plan performance for case-mix.
Main Outcome Measure
DMARD receipt (yes/no).
Results
The mean age of patients was 74 years; 75% were female, and 82% were white. Overall performance on the HEDIS RA measure was 59% in 2005, rising to 67% in 2008 (p for trend <.01). The largest difference in performance was based on age: patients ≥ 85 had a 30% (29%, 32%), p<.001) point lower rate of DMARD receipt compared to patients 65–69, even after adjusting for other factors. Males (−3%, 95% CI (−5%, −2%), p<.001), blacks (−4%, 95% CI (−6%, −2%), p<.001), patients with low personal income(−6%, 95% CI (−8%,−5%), p<.001), and those with the lowest ZIP-code-based socioeconomic status (SES) (−4%, 95% CI (−6%,−2%), p<.001) were also found to have lower percentage point rates, as were patients in the Middle (−7%, 95% CI (−13%,−2%), p<.001) and South Atlantic regions (−11%, 95% CI (−20%,−3%), p<.001, compared to the Pacific) and patients enrolled in for-profit health plans (−4%, 95% CI (−7%,−0%), p<.001). Performance varied widely by health plan, ranging from 16% to 87%.
Conclusions
Among Medicare managed care enrollees carrying a diagnosis of RA between 2005 and 2008, 63% received a DMARD; DMARD receipt varied based on demographic factors, SES, geographic location, and health plan.